Positron emission tomography (PET) using [18F]-fluoro-2-deoxy-D-glucose (FDG) as the
radiopharmaceutical agent was introduced in the late 1990s and has been widely used in …

The D-glucose analogue 2-(fluorine-18) fluoro-2-deoxy-D-glucose (FDG) is the most
commonly used radionuclide in positron emission tomography (PET) of the thorax …

Positron emission tomography (PET) is emerging as a powerful tool that complements
conventional radiologic assessment (chest radiographs, CT scans, MR imaging) of thoracic …

Over the past several years, positron emission tomography (PET) has become a clinically
useful, noninvasive study which complements conventional imaging (chest radiographs …

Radiographic imaging techniques have proved to be of limited value in characterizing chest
masses. Likewise, scintigraphic techniques with tumor-seeking single photon emitting …

Abstract 18 F-fluorodeoxyglucose (FDG) PET imaging provides physiologic and metabolic
information that characterizes lesions that are indeterminate by CT. FDG PET imaging is …

Metabolic imaging with positron emission tomography (PET) using 18F-fluoro-2-deoxy-
glucose (FDG) has been accepted as an important imaging modality in lung cancer. FDG …

Over the past years, positron emission tomography (PET) with fluoro-2-deoxy-d-glucose
(FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been …

Positron emission tomography (PET) was developed in the mid-1970, and its initial
applications were for heart and brain imaging research. Nowadays, this technology is aimed …

Abstract Positron emission tomography with 2-(18 F)-fluoro-2-deoxy-D-glucose (FDG-PET)
is a metabolic imaging technique. FDG-PET is more accurate than CT for the evaluation of …